{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:34:43Z","timestamp":1792712083398,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.amjcard.2025.04.013","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:37:07Z","timestamp":1745325427000},"page":"20-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The Impact of Inclisiran on Lipid Profiles in Adults with Hyperlipidemia: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8995-1058","authenticated-orcid":false,"given":"Ibrahim","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Turzo","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2025.04.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112227","article-title":"Inclisiran in lipid management: a literature overview and future perspectives","volume":"143","author":"Scicchitano","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.amjcard.2025.04.013_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12944-024-02294-8","article-title":"Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999-2018 study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.amjcard.2025.04.013_bib0003","article-title":"Real-world efficacy and safety of inclisiran: a single-country, multicenter, observational study (CHOLINET Registry)","author":"Gargiulo","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.04.013_bib0004","article-title":"Inclisiran versus alirocumab in improving lipid profile parameters: a systematic review and meta-analysis","author":"Saad Cleto","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2025.04.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.07.008","article-title":"Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems","author":"Wei","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.04.013_bib0006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjcard.2025.04.013_bib0007","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.amjcard.2025.04.013_bib0008","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.amjcard.2025.04.013_bib0009","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/heartjnl-2024-324052","article-title":"Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study","volume":"110","author":"Mihaylova","year":"2024","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.amjcard.2025.04.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"issue":"Pt A","key":"10.1016\/j.amjcard.2025.04.013_bib0011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.amjcard.2025.04.013_bib0012","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2288-11-41","article-title":"Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics","volume":"11","author":"Bowden","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.1016\/j.amjcard.2025.04.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.amjcard.2025.04.013_bib0014","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjcard.2025.04.013_bib0015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.04.013_bib0016","first-page":"3143","volume":"106","year":"2002"},{"issue":"1","key":"10.1016\/j.amjcard.2025.04.013_bib0017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12944-024-02294-8","article-title":"Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999-2018 study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"13","key":"10.1016\/j.amjcard.2025.04.013_bib0018","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1161\/CIR.0000000000000467","article-title":"Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the million hearts longitudinal ASCVD risk assessment tool: a special report from the American Heart Association and American College of Cardiology","volume":"135","author":"Lloyd-Jones","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2025.04.013_bib0019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. 10.1093\/eurheartj\/ehz826)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.amjcard.2025.04.013_bib0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjcard.2025.04.013_bib0021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval (Erratum in: Drugs. 2021 Jun;81(9):1129. 10.1007\/s40265-021-01529-7)","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.amjcard.2025.04.013_bib0022","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \"Inclisiran first\" strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.04.013_bib0023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diab Endocrinol"},{"issue":"12","key":"10.1016\/j.amjcard.2025.04.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101409","article-title":"Association of lipoprotein(a) with major adverse cardiovascular events across hs-CRP: a systematic review and meta-analysis","volume":"3","author":"Alebna","year":"2024","journal-title":"JACC Adv"},{"issue":"2","key":"10.1016\/j.amjcard.2025.04.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101549","article-title":"Impact of proprotein convertase subtilisin\/Kexin type 9 inhibitors on lipoprotein(a): a meta-analysis and meta-regression of randomized controlled trials","volume":"4","author":"Rivera","year":"2025","journal-title":"JACC Adv."},{"issue":"6","key":"10.1016\/j.amjcard.2025.04.013_bib0026","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"issue":"18","key":"10.1016\/j.amjcard.2025.04.013_bib0027","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J Biol Chem"},{"issue":"10057","key":"10.1016\/j.amjcard.2025.04.013_bib0028","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.amjcard.2025.04.013_bib0029","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2025.04.013_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cca.2022.11.018","article-title":"Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition","volume":"538","author":"Ouyang","year":"2023","journal-title":"Clin Chim Acta"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925002589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925002589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:17:36Z","timestamp":1778213856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925002589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S0002914925002589"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.04.013","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Inclisiran on Lipid Profiles in Adults with Hyperlipidemia: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}